全文获取类型
收费全文 | 700篇 |
免费 | 33篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 14篇 |
妇产科学 | 26篇 |
基础医学 | 74篇 |
口腔科学 | 34篇 |
临床医学 | 73篇 |
内科学 | 167篇 |
皮肤病学 | 3篇 |
神经病学 | 36篇 |
特种医学 | 83篇 |
外科学 | 29篇 |
综合类 | 19篇 |
预防医学 | 52篇 |
眼科学 | 3篇 |
药学 | 40篇 |
中国医学 | 1篇 |
肿瘤学 | 86篇 |
出版年
2023年 | 4篇 |
2022年 | 4篇 |
2021年 | 10篇 |
2020年 | 8篇 |
2019年 | 10篇 |
2018年 | 10篇 |
2017年 | 11篇 |
2016年 | 12篇 |
2015年 | 15篇 |
2014年 | 17篇 |
2013年 | 21篇 |
2012年 | 19篇 |
2011年 | 24篇 |
2010年 | 26篇 |
2009年 | 33篇 |
2008年 | 27篇 |
2007年 | 31篇 |
2006年 | 22篇 |
2005年 | 21篇 |
2004年 | 14篇 |
2003年 | 13篇 |
2002年 | 8篇 |
2001年 | 19篇 |
2000年 | 19篇 |
1999年 | 14篇 |
1998年 | 37篇 |
1997年 | 37篇 |
1996年 | 35篇 |
1995年 | 28篇 |
1994年 | 18篇 |
1993年 | 21篇 |
1992年 | 14篇 |
1991年 | 4篇 |
1990年 | 14篇 |
1989年 | 20篇 |
1988年 | 22篇 |
1987年 | 23篇 |
1986年 | 10篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 5篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1975年 | 5篇 |
1974年 | 6篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有745条查询结果,搜索用时 24 毫秒
1.
2.
3.
4.
Studies of proteins that inhibit tissue factor activity have generally been conducted using either an extracted tissue homogenate ("thromboplastin") or tissue factor protein reconstituted into phospholipid vesicles rather than with tissue factor expressed in cell membranes (its physiological environment). In the present study, a human fibroblast cell strain was used to evaluate the effects of lipoprotein associated coagulation inhibitor (LACI), placental anticoagulant protein (PAP), and apolipoprotein A-II (apo A-II) on human tissue factor in cell membranes. LACI was tested from 7.8 to 500 pmol/L on fibroblasts cultured at cell densities ranging from 3,500 to 9,925 cells/well, and caused a progressive inhibition of tissue factor activity. PAP was tested from 3.9 nmol/L to 1 mumol/L at cell densities ranging from 4,500 to 15,400 cells/well and caused up to 83% inhibition of tissue factor activity. Inhibition by these proteins appeared to be influenced by cell density as well as whether the cells were intact or disrupted. Apo A-II, up to 1 mumol/L, did not inhibit the tissue factor activity of intact or disrupted fibroblasts at any cell density examined even though it did inhibit the activity of tissue factor in phospholipid vesicles. Of these inhibitors of tissue factor-dependent activation of factor X, LACI was the most effective in suppressing the generation of factor Xa activity. The effects obtained with apo A-II are clearly dependent on the nature of the tissue factor preparation with which it is tested. The disparity between the inhibitory effect of apo A-II on the activity of tissue factor reconstituted into lipid vesicles and the absence of effect on the activity of tissue factor remaining in cell membranes serves to reemphasize the necessity of reexamining results obtained with model systems using as nearly physiological reagents as possible. 相似文献
5.
J. M. Rijnkels T. Smid E. C. Van den Aker A. Burdorf R. G. Van Wijk D. J. J. Heederik G. F. Houben H. Van Loveren T. M. Pal F. G. B. G. J. Van Rooy J. S. Van der Zee 《Allergy》2008,63(12):1593-1596
The Health Council of the Netherlands published a report in which the best procedure and method for recommending health‐based occupational exposure limits (OELs) for inhaled allergens were identified by evaluating the scientific state of the art. Many respiratory disorders in the workplace arise from inhalation of substances which can cause allergy. To protect workers against respiratory allergy, various preventive measures are taken, one of them being reduction of exposure by setting legally binding standards. These are based on health‐based OELs that specify a level of exposure to an airborne substance, a threshold level, below which it may reasonably be expected that there is no risk of adverse health effects. The Council is of the opinion that an OEL should prevent against allergic sensitization, as sensitization plays a crucial biological role and is a prerequisite for the development of allergy. Furthermore, the Council considers it most likely that the exposure level below which no allergic sensitization develops for most allergens is so low, that OELs are difficult to set with the current knowledge and technical feasibilities. An alternative approach is to accept exposure, which carries a small predefined risk in developing allergic sensitization. In addition, it is worth considering periodic screening of exposed workers on allergic sensitization, because timely intervention can prevent worse. The feasibility of periodic screening and what else is needed to comply with the most important criteria, should however be judged case‐by‐case. 相似文献
6.
It has been questioned whether the interaction of H2-antagonists with cytochrome P-450 that is observedin vitro is also relevant for thein vivo situation. Until now the possibility that cytochrome P-450 may function with different modes of action has been neglected in this respect. We studied the effect of cimetidine, ranitidine and famotidine on the monoxygenase, the oxidase and the peroxidase action of cytochrome P-450. Biotransformation catalyzed by the monoxygenase and oxidase action of cytochrome P-450 was affected by cimetidine (probably via its ligand interaction with cytochrome P-450), whereas metabolism by the peroxidase mode of action of cytochrome P-450 was hardly influenced. Ranitidine and famotidine (both pharmacodynamically more potent than cimetidine) only slightly affected cytochrome P-450 activities. 相似文献
7.
Myosin VIIA gene: heterogeneity of the mutations responsible for Usher syndrome type IB 总被引:8,自引:1,他引:8
Levy G; Levi-Acobas F; Blanchard S; Gerber S; Larget-Piet D; Chenal V; Liu XZ; Newton V; Steel KP; Brown SD; Munnich A; Kaplan J; Petit C; Weil D 《Human molecular genetics》1997,6(1):111-116
Usher syndrome is recognized as the most frequent cause of hereditary
deaf-blindness. Usher syndrome type I (USH1), the most severe form of the
disease, is characterized by profound congenital sensorineural deafness,
constant vestibular dysfunction, and retinitis pigmentosa of prepubertal
onset. This form is genetically heterogeneous and five loci (USH1A-E) have
been mapped thusfar. However, only the gene responsible for USH1 B (which
accounts for approximately 75% of USH1 cases) has been characterized. It
encodes a long-tailed unconventional myosin, myosin VIIA, with a predicted
2215 amino acid sequence. Primers covering the complete myosin VIIA coding
sequence as well as the 3' non coding sequence were designed, allowing
direct sequence analysis of each of the 48 coding exons and flanking splice
sites in seven patients affected by USH1. Four novel mutations were thereby
identified. The possibility should now be considered of a sequence-based
prenatal diagnosis in some of the families affected by this very severe
form of Usher syndrome.
相似文献
8.
9.
10.